NorthWest Biotherapeutics Inc (NWBO)

[Tadasana]

TF, Dr.Liau

We have a subgroup of patients, maybe 25 or 30 percent, who do really well after the treatment. What is puzzling is why the other 70 to 75 percent don’t do as well. What’s different? Their tumors look the same. Figuring out the reason for this variation in response has been the focus of my lab over the last 10 years, and we are moving toward new ways to personalize treatments based on predictors of response

She reiterates long term OS for 25-30 percent of patients after DC-VAX L treatment.
Add CI, Direct and we may have the rest 70-75 percent solved.